This study aims to evaluate the therapeutic activity and side effects of 16 mg/day dexamethasone in comparison to equivalent dose of MP (1mg/kg/day)for the management of COVID-19 infected patients.Moreover, and according to the importance of the IL-6/STAT-3 in triggering the inflammatory cascade and as the miRNAs are considered as prognostic markers, hence, the study aims also to study the impact of the used regimens on these biomarkers
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
60
Patients will receive dexamethasone 8 mg q12hours
Patients will receive 1mg/kg/day in 2 divided doses over 30 minutes
Eman Osama
Cairo, Egypt
RECRUITING28 days in hospital mortality
all patients who will die in 28 days from the start of treatment
Time frame: 28 days
WHO clinical progression scale
WHO clinical progression scale
Time frame: 10 days
Adverse events related to steroids
incidence of infection or hyperglycemia
Time frame: 10 days
Duration of ICU stay
Duration of ICU stay
Time frame: 10 days
Duration of high oxygen supplementation
Duration of high oxygen supplementation
Time frame: 10 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.